Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AVITA Medical (RCEL) Cash & Equivalents (2018 - 2025)

AVITA Medical (RCEL) has disclosed Cash & Equivalents for 5 consecutive years, with $8.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Equivalents fell 40.21% year-over-year to $8.4 million, compared with a TTM value of $8.4 million through Dec 2025, down 40.21%, and an annual FY2025 reading of $8.4 million, down 40.21% over the prior year.
  • Cash & Equivalents was $8.4 million for Q4 2025 at AVITA Medical, down from $15.4 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $50.9 million in Q3 2023 and bottomed at $8.4 million in Q4 2025.
  • Average Cash & Equivalents over 4 years is $19.8 million, with a median of $14.7 million recorded in 2024.
  • The sharpest move saw Cash & Equivalents skyrocketed 192.26% in 2023, then crashed 73.85% in 2024.
  • Year by year, Cash & Equivalents stood at $18.2 million in 2022, then crashed by 37.24% to $11.4 million in 2023, then grew by 23.25% to $14.0 million in 2024, then crashed by 40.21% to $8.4 million in 2025.
  • Business Quant data shows Cash & Equivalents for RCEL at $8.4 million in Q4 2025, $15.4 million in Q3 2025, and $10.6 million in Q2 2025.